HiChem in endotoxin diagnostics deal with Sepsis:
This article was originally published in Clinica
HiChem Diagnostics of Smithfield, Rhode Island, will acquire exclusive worldwide marketing rights to Sepsis' products for use in the rapid detection of endotoxin-related infection in critically ill patients. Sepsis' technology will provide test results in under 30 minutes, compared with 24 to 72 hours required with traditional diagnosis. Sepsis, a division of Toronto-based Spectral Diagnostics, will receive development and licensing fees, as well as milestone payments up to $6 million during the development phase. Further milestone payments will follow. Smithfield, Rhode Island-based HiChem, a subsidiary of Elan Pharmaceuticals, will also buy a 7.5% equity interest in Sepsis for $2 million.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.